Posted by Michael Wonder on 11 Jan 2023
Lupin and Exeltis announce reimbursement approval of NaMuscla in Spain for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic disorders
9 January 2023 - Agreement enables sustainable patient access of the only EU approved treatment for myotonia symptoms in non-dystrophic myotonic disorders.
Lupin and Exeltis Healthcare announced today that the Spanish Ministry of Health (MSCBC) has approved the reimbursement of Lupin’s NaMuscla (mexiletine) for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic disorders on the National Health and Pharmacy Service.
